Vamikibart Shows Early Safety in Uveitic Macular Edema - Summary - MDSpire
Commentary & Perspectives

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

  • By

  • Kerri Miller

  • May 7, 2026

  • 3 min

Share

The DOVETAIL trial evaluated the safety and tolerability of vamikibart, an intravitreal anti-interleukin-6 monoclonal antibody, for noninfectious uveitic macular edema. Unlike the POINT trial, which reported significant intraocular pressure increases with dexamethasone, vamikibart showed no sustained pressure elevations or cataract formation. While preliminary visual outcomes were promising and significant fluid resolution occurred, results should be interpreted with caution due to the trial's small size and lack of randomized controls. Ongoing phase 3 trials will further investigate vamikibart's efficacy.

Original Source(s)

Vamikibart Shows Early Safety in Uveitic Macular Edema

  • by Kerri Miller

  • May 7, 2026

Related Content

Phase 3 Win for TED Therapy

Amgen’s subcutaneous TEPEZZA meets phase 3 endpoints in thyroid eye disease

  • May 8, 2026

  • 3 min
Retinal Ischemia as Stroke Warning

Retrospective study investigates links between acute ischemic ocular events and increased stroke risk

  • May 8, 2026

  • 3 min
Chatbots Enter Retinal Care

New research shows how conversational AI might improve patient understanding and engagement in retinal detachment pathways

  • May 7, 2026

  • 3 min